R&D In Brief: Imaging Agent Approvals, EULAR Updates, Post-ASCO Cancer Data
This article was originally published in The Pink Sheet Daily
FDA approves new oncology imaging agents and a long-acting hemophilia drug; Sanofi/Regeneron present positive Phase III on RA drug sarilumab; biosimilar infliximab shows no meaningful differences to Remicade; Imbruvica response rates improved with umblituximab; Cyramza fails survival endpoint in liver cancer.
You may also be interested in...
Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?
A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.
Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix
Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.
At J.P. Morgan, Ironwood, Shire and Biogen Idec Contemplate What’s Next
A trio of companies offer insight into their latest strategies from interviews and presentations at the recent J.P. Morgan Healthcare conference: Ironwood’s development pipeline includes seven GI drugs; R&D consolidation and pipeline review at Shire; Biogen preps for hemophilia market and MS pricing pressures.